Actively Recruiting
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
Led by Sichuan University · Updated on 2023-11-01
20
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this single-arm, prospective study is to test in low-burden B-cell lymphoblastic leukemia (B-ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • The efficacy and safety of short-term blinatumomab as a bridging therapy to allo-HSCT in patients with low-burden B-ALL. Participants will take intravenous blinatumomab prior to allo-HSCT with an initial dosage of 8 μg/day. The dosage gradually escalated to 28 μg/day and continued for 5 to 10 days. Dexamethasone 20mg was administered 1 hour before the onset of blinatumomab infusion.
CONDITIONS
Official Title
Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with B-cell acute lymphoblastic leukemia (B-ALL)
- Age 16 years or older
- Availability of disease status records before and after transplantation
You will not qualify if you...
- Use of blinatumomab therapy for more than 14 days
- Leukemia burden of 10% or higher before treatment
- Severe organ dysfunction such as myocardial infarction, chronic heart failure, decompensated liver dysfunction, renal dysfunction, or gastrointestinal dysfunction
- Presence of central nervous system leukemia
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital of Sichuan University
Chengdu, Sichuan, China, 610044
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here